News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
256,421 Results
Type
Article (13724)
Company Profile (256)
Press Release (242441)
Section
Business (79175)
Career Advice (147)
Deals (13164)
Drug Delivery (28)
Drug Development (50147)
Employer Resources (31)
FDA (5633)
Job Trends (5103)
News (143608)
Policy (10011)
Tag
Academia (900)
Africa (145)
Allergies (30)
Alliances (21407)
Alzheimer's disease (685)
Antibody-drug conjugate (ADC) (31)
Approvals (5598)
Arizona (38)
Artificial intelligence (29)
Asia (16640)
Australia (2780)
Bankruptcy (96)
Best Places to Work (4347)
Biotechnology (214)
C2C Services and Suppliers (10603)
California (1226)
Canada (501)
Cancer (302)
Career advice (128)
CAR-T (33)
Cell therapy (95)
China (90)
Clinical research (39049)
Collaboration (85)
Colorado (40)
Compensation (40)
Connecticut (43)
COVID-19 (978)
Cystic fibrosis (58)
Data (226)
Diabetes (38)
Diagnostics (1157)
Earnings (28367)
Employer resources (29)
Europe (35732)
Events (45794)
Executive appointments (99)
FDA (5749)
Florida (122)
Funding (99)
Gene editing (28)
Gene therapy (81)
GLP-1 (263)
Government (1052)
Healthcare (6510)
Hotbed/Location (184113)
Illinois (74)
Indiana (43)
Infectious disease (988)
Inflammatory bowel disease (79)
IPO (7136)
Job creations (856)
Job search strategy (124)
Kansas (52)
Layoffs (177)
Legal (1369)
Lung cancer (70)
Manufacturing (28)
Maryland (187)
Massachusetts (998)
Medical device (2514)
Medtech (2515)
Mergers & acquisitions (6035)
Metabolic disorders (132)
Michigan (38)
Minnesota (65)
Neuroscience (793)
New Jersey (331)
New York (397)
NextGen Class of 2024 (1975)
Non-profit (837)
North Carolina (326)
Northern California (532)
Obesity (76)
Ohio (62)
Opinion (86)
Parkinson's disease (31)
Patents (36)
Pennsylvania (277)
People (24702)
Pharmaceutical (41)
Phase I (13699)
Phase II (18163)
Phase III (11549)
Pipeline (77)
Postmarket research (842)
Preclinical (5767)
Press Release (30)
Rare diseases (102)
Real estate (1406)
Regulatory (8020)
Research institute (928)
South America (206)
Southern California (509)
Startups (1963)
Texas (114)
United States (4693)
Vaccines (132)
Washington State (154)
Weight loss (59)
Date
Today (65)
Last 7 days (384)
Last 30 days (1385)
Last 365 days (21419)
2024 (15102)
2023 (22412)
2022 (26822)
2021 (27806)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13753)
2016 (11852)
2015 (14366)
2014 (10401)
2013 (7484)
2012 (7532)
2011 (7615)
2010 (7428)
256,421 Results for "astria therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 04, 2024
Astria Therapeutics, Inc., a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 40,000 shares of Astria’s common stock on June 3, 2024 under Astria’s 2022 Inducement Stock Incentive Plan.
June 4, 2024
·
1 min read
Genetown
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress
Astria Therapeutics, Inc. today announced that it will present two posters at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain on June 1, 2024.
May 23, 2024
·
1 min read
Genetown
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 02, 2024
Astria Therapeutics, Inc., a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 173,500 shares of Astria’s common stock on May 1, 2024 under Astria’s 2022 Inducement Stock Incentive Plan.
May 2, 2024
·
1 min read
Press Releases
Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress
September 19, 2024
·
1 min read
Genetown
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference - May 30, 2024
Astria Therapeutics, Inc. today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference on Thursday, June 6th at 10:00am ET in New York, NY.
May 30, 2024
·
1 min read
Genetown
Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting
Astria Therapeutics, Inc. today announced that it will present information on the preclinical profile of STAR-0310 at the upcoming Society for Investigative Dermatology (SID) Annual Meeting in Dallas, Texas on May 16, 2024.
May 8, 2024
·
1 min read
Genetown
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference - May 24, 2024
Astria Therapeutics, Inc., a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, announced that it will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allergy Conference in Palm Beach, Florida on June 1, 2024.
May 24, 2024
·
1 min read
Genetown
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 03, 2024
Astria Therapeutics, Inc., a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 9,000 shares of Astria’s common stock on April 1, 2024 under Astria’s 2022 Inducement Stock Incentive Plan.
April 3, 2024
·
1 min read
Business
Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
May 9, 2024
·
13 min read
Genetown
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 05, 2024
Astria Therapeutics, Inc., a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 40,000 shares of Astria’s common stock on March 1, 2024 under Astria’s 2022 Inducement Stock Incentive Plan.
March 5, 2024
·
1 min read
1 of 25,643
Next
